SINGAPORE ∩╗┐AND TORONTO, ONTARIO--(Marketwired - Oct. 11, 2013) - 360ip and the Canadian Centre for Commercialization of Regenerative Medicine (CCRM) are signing a collaboration agreement to work together in a variety of areas, including developing a fund to invest in best-in-class regenerative medicine (RM) technologies and companies in Asia, Europe and North America.
"360ip has expertise in identifying, commercializing and monetizing intellectual property [IP] worldwide with a particular focus in Asia," explains Asashi Fujimori, SVP of 360ip and Representative Director of 360ip JAPAN. "CCRM has built up an excellent network of leading academic and industry partners in the RM field, and combined with our strengths and contacts, we expect great things to come from this partnership."
"It benefits Canada if CCRM is sourcing best-in-class RM IP from around the world and this affiliation opens the doors for CCRM to do just that," says Michael May, CEO of CCRM. "This fund is an exciting undertaking that will be good for the global community. I'm very pleased that CCRM's value has been recognized internationally and we look forward to collaborating with 360ip, a commercialization leader in the Asian market."
360ip JAPAN, a 360ip affiliate, provides technology commercialization, investment and fund management expertise across a variety of industries with a particular emphasis on the life sciences. 360ip JAPAN was recently selected by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) to serve as a Project Promoter under the STart-ups from Advanced Research and Technology (START) Program. 360ip JAPAN's area of focus for this program is regenerative medicine and it will work closely with CCRM to identify marketable IP.
Representatives from 360ip and CCRM are currently attending Bio Japan 2013 in Yokohama, Japan, from October 9-11 http://www.ics-expo.jp/biojapan/seminar_schedule.html. Dr. Allison Brown, Director of Commercialization for CCRM, presented "Overview of Canada's Public-Private Partnership in Commercialization of Stem Cell Research - A Focus on Stem Cell-based Predictive Drug Screening" on Oct. 9th. For a copy of her presentation, contact CCRM.
About 360ip Pte Ltd ("360ip")
360ip is a global technology commercialization, investment and fund management company, headquartered in Singapore, with teams based throughout Asia and North America. 360ip includes an experienced group of operational, technical and financial professionals with a strong track record in technology commercialization and investment in high-growth companies.
360ip was jointly established by Battelle Memorial Institute ("Battelle"), the world's largest nonprofit R&D and commercialization organization, and Battelle Ventures, the venture capital firm affiliated with Battelle. Battelle, which began operations in 1929, generates more than US$6.0 billion in consolidated annual revenue, oversees more than 22,000 employees worldwide and has extensive life science-related capabilities and facilities. Battelle Ventures - whose sole limited partner is Battelle - and its affiliate fund, Innovation Valley Partners, have a combined US$255 million under management. Development Bank of Japan is also a shareholder of 360ip, and the companies have entered into a strategic collaboration in Japan.
About the Centre for Commercialization of Regenerative Medicine (CCRM)
CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011. CCRM is hosted by the University of Toronto.